Paradigm Announces Molecular Profiling Collaboration with TESARO, Inc. - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Paradigm Announces Molecular Profiling Collaboration with TESARO, Inc. Collaboration will enhance clinical trials by identifying proteomic and other predictors of response to targeted cancer therapies.


Paradigm Announces Molecular Profiling Collaboration with TESARO, Inc.

Collaboration will enhance clinical trials by identifying proteomic and other predictors of response to targeted cancer therapies.

PR Newswire

ANN ARBOR, Mich. and PHOENIX, Aug. 20, 2014 /PRNewswire-USNewswire/ -- Paradigm, a non-profit corporation established to bring cutting-edge next-generation sequencing and proteomic diagnostics and biomarker driven clinical trials to cancer patients, today announced a collaboration with TESARO, Inc.  Paradigm will use its advanced molecular capabilities to characterize patient tissue samples from clinical trials to better predict which patients may be sensitive or resistant to TESARO's TSR-011.  This may lead to more successful clinical trial outcomes as well as enable Paradigm to develop and commercialize potential diagnostic products. 

Paradigm Logo

Robert J. Penny MD, PhD, CEO of Paradigm noted "Paradigm  is utilizing decades of know how in successfully working with the pharmaceutical and diagnostic industry and merging those with our unique academic research abilities to craft personalized interrogations for clinical trial selection and provide accelerated translational treatment decisions in patient care."

ABOUT PARADIGM

Paradigm is a non-profit molecular information corporation established to bring cutting-edge diagnostics to cancer patients and clinical trials by providing information about the genomic makeup of the patient's cancer and potential therapies based on the specific characterization of the patient's tumor that can impact the patient's course of treatment. Paradigm's Next-Generation Sequencing based diagnostic test PCDx provides oncologists and patients with more precise information about the specific cancer pathways in the patient and associations between the pathways and the specific drugs available that can affect the cancer to allow for more effective decision-making. The test is driven by supporting data and literature and provides more choices for patient care than currently available on the market. For more information visit www.paradigmdx.org.

Follow Paradigm on Twitter: @Paradigm_Dx

Logo - http://photos.prnewswire.com/prnh/20140819/137529

SOURCE Paradigm

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document

Click here